Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-Term Post-Marketing Safety Study of Yescarta® (axicabtagene ciloleucel)

Trial Profile

A Long-Term Post-Marketing Safety Study of Yescarta® (axicabtagene ciloleucel)

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axicabtagene ciloleucel (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Dec 2022 Results by deriving data from CIBMTR registry and other study; comparing effectiveness outcomes between treatment with either axicel or chemoimmunotherapy in an elderly population in real-world settings, presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 09 Sep 2020 New trial record
    • 08 Sep 2020 Status changed to active no longer recruiting, according to a Center for International Blood and Marrow Transplant Research media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top